Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Invivyd logo — Vaccines can only take us so far. Antibodies are the natural...

Invivyd

Vaccines can only take us so far. Antibodies are the natural next step.

Founded 2020 United States New Haven, United States 177 employees IPO Total: $863.50M Biotechnology, Health and Wellness +1

General Information

Company Name Invivyd
Founded Year 2020
Location United States New Haven, United States
Employees 177
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage IPO
Business Model B2B, B2D
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Invivyd. To contact Invivyd, visit invivyd.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Invivyd compare?

A PDF of Invivyd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Invivyd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Invivyd

Invivyd is a pioneering player in the biotechnology sector, founded in 2020 and headquartered in the United States. The company specializes in developing monoclonal antibodies that can address evolving viruses more effectively than the human immune system. Its proprietary technology platform sets it apart, capable of monitoring and adapting drug formulations to deliver best-in-class antibodies.

A notable milestone was achieved in March 2024 when Invivyd received emergency use authorization from the U.S. FDA for one of its monoclonal antibody candidates, underlining its capability in addressing urgent health concerns, such as COVID-19.

The company operates within the Biotechnology, Health and Wellness, and Pharmaceutical industries, and most recently raised capital through a Post IPO Equity investment on 01 November 2025. Investors should consider Invivyd's robust technology platform, recent regulatory achievements, and its potential to meet the growing demand for adaptive and high-efficacy treatments.

Business keywords: Monoclonal Antibody Development, Virus Evolution Resistance, Proprietary Technology Platform, Emergency Use Authorization, Innovative Antibody Candidates, Antibody-based Therapies, SARS-CoV-2 Treatment, Immunocompromised Protection, Viral Threat Mitigation, Biopharmaceuticals, Integrated Drug Assessment, Antibody Potency Enhancement

Services & Products

Antibody Development
Viral Disease Treatment
Research and Development
Clinical Trials
Education on Antibodies

Target Customers

Healthcare Providers Patients with Infectious Diseases Long COVID Patients Vaccine Injured Individuals Pharmaceutical Partners

Pricing

as listed on Sep 29, 2026

On request

Invivyd's pricing page

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity Undisclosed -
01 Nov 2025
Post-IPO Equity $57.50M -
01 Aug 2025
Post-IPO Debt $30.00M 1
Silicon Valley Bank
01 Apr 2025
IPO $310.00M -
01 Aug 2021
Series C $336.00M 13
Mithril Capital Polaris Partners RA Capital Management
Mithril Capital, Polaris Partners +11
01 Apr 2021
Series B $80.00M 5
GV Mithril Capital Polaris Partners
GV, Mithril Capital +3
01 Nov 2020
Series A $50.00M 2
Mithril Capital Polaris Partners
Mithril Capital, Polaris Partners
01 Jul 2020

Invivyd Alternatives & Competitors

View All Alternatives
Invivyd vs
Mestag Therapeutics
Mestag Therapeutics United Kingdom

New therapies for inflammatory disease and cancer by targeting fibroblast immunology

Seed
40 employees
Biotechnology, Health Care
Compare Invivyd vs Mestag Therapeutics
Invivyd vs
REGENXBIO
REGENXBIO United States

Seeking to improve lives through the curative potential of gene therapy.

IPO
389 employees
Biopharma, Biotechnology
Compare Invivyd vs REGENXBIO
Invivyd vs
CV6 Therapeutics, (NI) Ltd.
CV6 Therapeutics, (NI) Ltd. United Kingdom

CV6 Therapeutics is dedicated to improving patients lives through the development of novel and innov...

Venture round
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About Invivyd

Vaccines can only take us so far. Antibodies are the natural next step.
Invivyd was founded in 2020.
Invivyd is headquartered in New Haven, United States.
Invivyd operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Monoclonal Antibody Development, Virus Evolution Resistance, Proprietary Technology Platform and Emergency Use Authorization. Its customers include Healthcare Providers, Patients with Infectious Diseases and Long COVID Patients.
Invivyd has a B2B and B2D business model. Its revenue comes from Product Sales, Licensing and Performance Based.
As listed on Invivyd's pricing page on Sep 29, 2026: On request.
Invivyd has approximately 177 employees.
Invivyd has completed 7 funding rounds, raising a total of $863.50M. The latest funding stage is IPO.
Invivyd offers: Antibody Development, Viral Disease Treatment, Research and Development, Clinical Trials, Education on Antibodies.
Top alternatives and competitors to Invivyd include Mestag Therapeutics, REGENXBIO, CV6 Therapeutics, (NI) Ltd., Verdiva Bio, Calluna Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Invivyd and Mestag Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Invivyd, https://bouncewatch.com/company/invivyd, updated 25 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout